Shin Kan

1.2k total citations
32 papers, 808 citations indexed

About

Shin Kan is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Shin Kan has authored 32 papers receiving a total of 808 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Immunology, 18 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Shin Kan's work include Immunotherapy and Immune Responses (15 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Immune Cell Function and Interaction (9 papers). Shin Kan is often cited by papers focused on Immunotherapy and Immune Responses (15 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Immune Cell Function and Interaction (9 papers). Shin Kan collaborates with scholars based in Japan, United States and France. Shin Kan's co-authors include Masato Okamoto, Shigeo Koido, Sadamu Homma, Masaki Ito, Marito Araki, Norio Komatsu, Soji Morishita, Yoshitaka Sunami, Akimichi Ohsaka and Yumi Hironaka and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Cancer Research.

In The Last Decade

Shin Kan

32 papers receiving 801 citations

Peers

Countries citing papers authored by Shin Kan

Since Specialization

Citations

This map shows the geographic impact of Shin Kan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shin Kan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shin Kan more than expected).

Fields of papers citing papers by Shin Kan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shin Kan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shin Kan. The network helps show where Shin Kan may publish in the future.

Co-authorship network of co-authors of Shin Kan

This figure shows the co-authorship network connecting the top 25 collaborators of Shin Kan. A scholar is included among the top collaborators of Shin Kan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shin Kan. Shin Kan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dendritic cells pulsed with multifunctional Wilms’ tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer 2024 ·Journal for ImmunoTherapy of Cancer ·Shigeo Koido, Junichi Taguchi, (unknown), Shin Kan, (unknown), Takeyuki Misawa, Zensho Ito, Kan Uchiyama, Masayuki Saruta, Shintaro Tsukinaga, Machi Suka, Hiroyuki Yanagisawa, Nobuhiro Sato, Toshifumi� Ohkusa, Shigetaka Shimodaira, Haruo Sugiyama	13
2	The stimulatory effect of fusobacteria on dendritic cells under aerobic or anaerobic conditions 2022 ·Scientific Reports ·Shigeo Koido, Sankichi Horiuchi, Shin Kan, (unknown), Zensho Ito, Kan Uchiyama, Masayuki Saruta, Nobuhiro Sato, Toshifumi� Ohkusa	4
3	Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma 2021 ·BMC Cancer ·(unknown), Zensho Ito, Machi Suka, (unknown), Shin Kan, Kan Uchiyama, Masayuki Saruta, (unknown), Yuki Takano, Shuichi Fujioka, Takeyuki Misawa, Takashi Yamauchi, Hiroyuki Yanagisawa, Nobuhiro Sato, Toshifumi� Ohkusa, Haruo Sugiyama, Shigeo Koido	27
4	Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1 2019 ·Oncology ·Zensho Ito, Shin Kan, (unknown), Sankichi Horiuchi, (unknown), Sayumi Yoshida, Mikio Kajihara, Atsushi Hokari, Masayuki Saruta, Noriyuki Yoshida, Masanori Kobayashi, Toshifumi� Ohkusa, Shigetaka Shimodaira, Masato Okamoto, Haruo Sugiyama, Shigeo Koido	10
5	Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms 2016 ·Blood ·Marito Araki, Yinjie Yang, Nami Masubuchi, Yumi Hironaka, (unknown), Soji Morishita, Yoshihisa Mizukami, Shin Kan, Shuichi Shirane, Yoko Edahiro, Yoshitaka Sunami, Akimichi Ohsaka, Norio Komatsu	194
6	Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine 2015 ·Oncology Reports ·Shin Kan, Shigeo Koido, Masato Okamoto, Kazumi Hayashi, Masaki Ito, Yuko Kamata, Hideo Komita, Takefumi Ishidao, Eijiro Nagasaki, Sadamu Homma	25
7	Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells 2015 ·BMC Cancer ·Shin Kan, Shigeo Koido, Masato Okamoto, Kazumi Hayashi, Masaki Ito, Yuko Kamata, Hideo Komita, Eijiro Nagasaki, Sadamu Homma	24
8	Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors 2015 ·Oncology Reports ·Hideo Komita, Shigeo Koido, Kazumi Hayashi, Shin Kan, Masaki Ito, Yuko Kamata, Masafumi Suzuki, Sadamu Homma	42
9	Induction of antigen-specific cytotoxic T lymphocytes by fusion cells generated from allogeneic plasmacytoid dendritic and tumor cells 2014 ·International Journal of Oncology ·Shigeo Koido, Sadamu Homma, Shin Kan, Kazuki Takakura, Yoshihisa Namiki, Hiroko Kobayashi, Zensho Ito, Kan Uchiyama, Mikio Kajihara, Seiji Arihiro, Hiroshi Arakawa, Masato Okamoto, Toshifumi Ohkusa, Jianlin Gong, Hisao Tajiri	8
10	Vaccination with vascular progenitor cells derived from induced pluripotent stem cells elicits antitumor immunity targeting vascular and tumor cells 2014 ·Cancer Immunology Immunotherapy ·Shigeo Koido, Masaki Ito, Yukiko Sagawa, Masato Okamoto, Kazumi Hayashi, Eijiro Nagasaki, Shin Kan, Hideo Komita, Yuko Kamata, Sadamu Homma	6
11	Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions 2013 ·OncoImmunology ·Shigeo Koido, Sadamu Homma, Masato Okamoto, Yoshihisa Namiki, Kazuki Takakura, Kan Uchiyama, Mikio Kajihara, Seiji Arihiro, Hiroo Imazu, Hiroshi Arakawa, Shin Kan, Hideo Komita, Yuko Kamata, Masaki Ito, Toshifumi Ohkusa, Jianlin Gong, Hisao Tajiri	11
12	Fusions between dendritic cells and whole tumor cells as anticancer vaccines 2013 ·OncoImmunology ·Shigeo Koido, Sadamu Homma, Masato Okamoto, Yoshihisa Namiki, Kazuki Takakura, Kan Uchiyama, Mikio Kajihara, Seiji Arihiro, Hiroo Imazu, Hiroshi Arakawa, Shin Kan, Hideo Komita, Masaki Ito, Toshifumi Ohkusa, Jianlin Gong, Hisao Tajiri	40
13	Prognostic Impact of Expression of Bcl-2 and Bax Genes in Circulating Immune Cells Derived from Patients with Head and Neck Carcinoma 2013 ·Neoplasia ·Tomoyuki Tano, Masato Okamoto, Shin Kan, Koh‐ichi Nakashiro, Shigetaka Shimodaira, Shigeo Koido, Sadamu Homma, Mitsunobu Sato, Tomonobu Fujita, Yutaka Kawakami, Hiroyuki Hamakawa	18
14	Immunochemoradiotherapy for Patients with Oral Squamous Cell Carcinoma: Augmentation of OK-432-Induced Helper T Cell 1 Response by 5-FU and X-ray Irradiation 2013 ·Neoplasia ·Tomoyuki Tano, Masato Okamoto, Shin Kan, Takashi Bando, Hiroyuki Goda, Koh‐ichi Nakashiro, Shigetaka Shimodaira, Shigeo Koido, Sadamu Homma, Tomonobu Fujita, Mitsunobu Sato, Naomi Yamashita, Hiroyuki Hamakawa, Yutaka Kawakami	17
15	Growth inhibition and apoptosis by an active component of OK-432, a streptococcal agent, via Toll-like receptor 4 in human head and neck cancer cell lines 2012 ·Oral Oncology ·Tomoyuki Tano, Masato Okamoto, Shin Kan, Koh‐ichi Nakashiro, Shigetaka Shimodaira, Naomi Yamashita, Yutaka Kawakami, Hiroyuki Hamakawa	13
16	Antitumor Effect of OK-432–Derived DNA 2006 ·Journal of Immunotherapy ·Tetsuya Oshikawa, Masato Okamoto, Tomoyuki Tano, (unknown), Shin Kan, Yoichiro Moriya, Yoshiki Ryoma, Motoo Saito, Shizuo Akira, Mitsunobu Sato	21
17	TX‐1877, a bifunctional hypoxic cell radiosensitizer, enhances anticancer host response: Immune cell migration and nitric oxide production 2005 ·International Journal of Cancer ·Tetsuya Oshikawa, Masato Okamoto, Sharif Ahmed, Sachiko Furuichi, Tomoyuki Tano, (unknown), Shin Kan, Soko Kasai, Yoshihiro Uto, Hideko Nagasawa, Hitoshi Hori, Mitsunobu Sato	8
18	Mechanism of Anticancer Host Response Induced by OK-432, a Streptococcal Preparation, Mediated by Phagocytosis and Toll-Like Receptor 4 Signaling 2005 ·Journal of Immunotherapy ·Masato Okamoto, Tetsuya Oshikawa, Tomoyuki Tano, Sharif Ahmed, Shin Kan, (unknown), Sachiko Akashi, Kensuke Miyake, Yoichiro Moriya, Yoshiki Ryoma, Motoo Saito, Mitsunobu Sato	55
19	Involvement of nitric oxide in anti-tumor effects of OK-432, a streptococcal anti-tumor immunotherapeutic agent 2005 ·International Immunopharmacology ·Tetsuya Oshikawa, Masato Okamoto, Tomoyuki Tano, Sharif Ahmed, (unknown), Shin Kan, Yoichiro Moriya, Yoshiki Ryoma, Motoo Saito, Mitsunobu Sato	5
20	Anti-Tumor Effect of an Intratumoral Administration of Dendritic Cells in Combination with TS-1, an Oral Fluoropyrimidine Anti-Cancer Drug, and OK-432, a Streptococcal Immunopotentiator 2004 ·Journal of Immunotherapy ·Sharif Ahmed, Masato Okamoto, Tetsuya Oshikawa, Tomoyuki Tano, (unknown), Shin Kan, (unknown), (unknown), Yoichiro Moriya, Yoshiki Ryoma, Motoo Saito, Mitsunobu Sato	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact